SCHEMBL2371753

SCHEMBL2371753

CCCC[Sn](CCCC)(CCCC)c1cc2c(=O)c3cc(Br)ccc3oc2nc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 6/20 0.45
KDM4E B2RXH2 4/20 0.39
HSD17B10 Q99714 2/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 4/20 0.38
MEN1 O00255 2/20 0.38
NPC1 O15118 6/20 0.36
RAB9A P51151 6/20 0.36
RXFP1 Q9HBX9 3/20 0.36
ALDH1A1 P00352 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35
MAPT P10636 1/20 0.35
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2370555 0.81 KDM4E (0.36) TBK1KDM4EPOLBKMT2AMEN1
SCHEMBL2372134 0.76 TBK1 (0.53) TBK1KDM4EHSD17B10POLBKMT2A
SCHEMBL2371734 0.70 TBK1 (0.54) TBK1KDM4EHSD17B10POLBKMT2A
SCHEMBL2371244 0.67 ACHE (0.39) KDM4EHSD17B10POLBKMT2ARXFP1
SCHEMBL2371403 0.67 TBK1 (0.48) TBK1KDM4EHSD17B10POLBKMT2A
SCHEMBL177371 0.66 TBK1 (0.55) TBK1KDM4EHSD17B10KMT2AMEN1
SCHEMBL2588529 0.65 PIM1 (0.58) TBK1KDM4EHSD17B10KMT2ANPC1
SCHEMBL29416622 0.65 PIM1 (0.58) TBK1KDM4EHSD17B10KMT2ANPC1
SCHEMBL21550359 0.64
SCHEMBL19180639 0.64 TBK1 (0.84) TBK1KDM4ENPC1RAB9ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883782-B2 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-11-11 US disclosed
EP-2547685-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS Amgen Inc. (US) 2013-01-23 EP disclosed
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP TBK1 2235/4885KDM4E 2994/4885HSD17B10 1766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.